Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads

Authors

  • Tai-Chung Tseng,

    1. Division of Gastroenterology, Department of Internal Medicine, Buddhist Tzu Chi General Hospital Taipei Branch, Taipei, Taiwan
    2. Graduate Institute of Clinical Medicine, Taipei, Taiwan
    3. School of Medicine, Tzu Chi University, Hualien, Taiwan
    Search for more papers by this author
  • Chun-Jen Liu,

    1. Division of Gastroenterology, Department of Internal Medicine, Taipei, Taiwan
    2. Graduate Institute of Clinical Medicine, Taipei, Taiwan
    Search for more papers by this author
  • Hung-Chih Yang,

    1. Division of Gastroenterology, Department of Internal Medicine, Taipei, Taiwan
    2. Departments of Microbiology, Taipei, Taiwan
    Search for more papers by this author
  • Tung-Hung Su,

    1. Division of Gastroenterology, Department of Internal Medicine, Taipei, Taiwan
    2. Graduate Institute of Clinical Medicine, Taipei, Taiwan
    Search for more papers by this author
  • Chia-Chi Wang,

    1. Division of Gastroenterology, Department of Internal Medicine, Buddhist Tzu Chi General Hospital Taipei Branch, Taipei, Taiwan
    2. School of Medicine, Tzu Chi University, Hualien, Taiwan
    Search for more papers by this author
  • Chi-Ling Chen,

    1. Graduate Institute of Clinical Medicine, Taipei, Taiwan
    Search for more papers by this author
  • Cheng-An Hsu,

    1. Laboratory Medicine, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan
    Search for more papers by this author
  • Stephanie Fang-Tzu Kuo,

    1. St. Vincent's Hospital, Melbourne, Victoria, Australia
    Search for more papers by this author
  • Chen-Hua Liu,

    1. Division of Gastroenterology, Department of Internal Medicine, Taipei, Taiwan
    2. Graduate Institute of Clinical Medicine, Taipei, Taiwan
    Search for more papers by this author
  • Pei-Jer Chen,

    1. Division of Gastroenterology, Department of Internal Medicine, Taipei, Taiwan
    2. Graduate Institute of Clinical Medicine, Taipei, Taiwan
    Search for more papers by this author
  • Ding-Shinn Chen,

    1. Division of Gastroenterology, Department of Internal Medicine, Taipei, Taiwan
    2. Graduate Institute of Clinical Medicine, Taipei, Taiwan
    Search for more papers by this author
  • Jia-Horng Kao

    Corresponding author
    1. Division of Gastroenterology, Department of Internal Medicine, Taipei, Taiwan
    2. Graduate Institute of Clinical Medicine, Taipei, Taiwan
    3. Hepatitis Research Center, and the Departments of Medical Research, Taipei, Taiwan
    4. Departments of Medical Research, Taipei, Taiwan
    • Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, 1 Chang-Te Street, Taipei 10002, Taiwan
    Search for more papers by this author
    • fax: (886)-2-23825962


  • Potential conflict of interest: Nothing to report.

Abstract

Chronic hepatitis B patients with high viral loads are at increased risk of cirrhosis and hepatocellular carcinoma (HCC). In patients with low viral loads, higher hepatitis B surface antigen (HBsAg) levels have been shown to predict HCC development. However, little is known about the difference in risk for other hepatitis B virus (HBV)-related adverse outcomes with varying HBsAg levels. A total of 1,068 Taiwanese hepatitis B e antigen (HBeAg)-negative HBV carriers with serum HBV DNA level <2,000 IU/mL at baseline were followed for a mean duration of 13.0 years. Patients were categorized based on their HBsAg levels, and the relationships between HBsAg level and development of HBeAg-negative hepatitis, hepatitis flare, and cirrhosis were investigated. Of the 1068 patients with low viral loads, 280 developed HBeAg-negative hepatitis, with an annual incidence rate of 2.0%. HBsAg level, but not HBV DNA level, was found to be a risk factor for HBeAg-negative hepatitis. Multivariate analysis showed that the adjusted hazard ratio in patients with an HBsAg level ≥1,000 versus <1000 IU/mL was 1.5 (95% confidence interval, 1.2–1.9). The positive correlation was present when evaluating other endpoints, including hepatitis flare and cirrhosis, and remained consistent when the study population was restricted to those with normal alanine aminotransferase (ALT) level at baseline. The annual incidence rate of HBeAg-negative hepatitis was lowered to 1.1% in patients with low levels of HBV DNA, HBsAg, and ALT. Conclusion: In HBeAg-negative patients with low viral loads and genotype B or C virus infection, a higher HBsAg level can predict disease progression. HBsAg <1,000 IU/mL in combination with low levels of HBV DNA and ALT help define minimal-risk HBV carriers. (HEPATOLOGY 2013)

Ancillary